Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRC | P12931 | 16/20 | 0.74 |
| ▸ | KDR | P35968 | 12/20 | 0.74 |
| ▸ | FGFR1 | P11362 | 11/20 | 0.74 |
| ▸ | PDGFRB | P09619 | 10/20 | 0.74 |
| ▸ | LCK | P06239 | 9/20 | 0.74 |
| ▸ | FYN | P06241 | 9/20 | 0.74 |
| ▸ | YES1 | P07947 | 9/20 | 0.74 |
| ▸ | MET | P08581 | 1/20 | 0.69 |
| ▸ | EGFR | P00533 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5410964 | 0.87 | KDR (0.60) | SRCKDRFGFR1PDGFRBLCK | |
| SCHEMBL6390071 | 0.86 | SRC (0.68) | SRCKDRFGFR1PDGFRBLCK | |
| SCHEMBL6390067 | 0.86 | SRC (0.68) | SRCKDRFGFR1PDGFRBLCK | |
| SCHEMBL4407079 | 0.85 | KDR (0.66) | SRCKDRFGFR1PDGFRBLCK | |
| SCHEMBL4407081 | 0.85 | KDR (0.66) | SRCKDRFGFR1PDGFRBLCK | |
| SCHEMBL6696492 | 0.85 | SRC (0.98) | SRCKDRFGFR1PDGFRBLCK | |
| SCHEMBL5408957 | 0.83 | MET (0.64) | SRCKDRFGFR1PDGFRBLCK | |
| SCHEMBL5408966 | 0.83 | MET (0.64) | SRCKDRFGFR1PDGFRBLCK | |
| SCHEMBL4404881 | 0.83 | KDR (0.82) | SRCKDRFGFR1PDGFRBLCK | |
| SCHEMBL4404878 | 0.83 | KDR (0.82) | SRCKDRFGFR1PDGFRBLCK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4562010-A1 | CRYSTALLINE FORMS OF AN AKR1C3 DEPENDENT KARS INHIBITOR | Novartis AG (CH) | 2025-06-04 | — | — | EP | disclosed |
| WO-2024023666-A1 | CRYSTALLINE FORMS OF AN AKR1C3 DEPENDENT KARS INHIBITOR | NOVARTIS AG (CH) | 2024-02-01 | — | — | WO | disclosed |
| EP-4007592-A1 | ANGIOTENSIN TYPE 2 (AT2) RECEPTOR AGONISTS FOR USE IN THE TREATMENT OF CANCER | LanthioPep B.V. (NL) | 2022-06-08 | — | — | EP | disclosed |